139 related articles for article (PubMed ID: 9513991)
1. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
Branović K; Gebauer B; Trescec A; Benko B
Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
[TBL] [Abstract][Full Text] [Related]
2. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
3. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
Teh LC
Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
[TBL] [Abstract][Full Text] [Related]
4. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
[TBL] [Abstract][Full Text] [Related]
5. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
6. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
[TBL] [Abstract][Full Text] [Related]
7. Preliminary clinical experience: pharmacokinetics and tolerance of a double-virus-inactivated factor VIII preparation.
Martinowitz U
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S84-5. PubMed ID: 7495976
[TBL] [Abstract][Full Text] [Related]
8. Large-scale preparation of a highly purified solvent-detergent treated factor VIII concentrate.
Myers R; Wickerhauser M; Charamella L; Simon L; Nummy W; Brodniewicz-Proba T
Vox Sang; 1991; 60(3):141-7. PubMed ID: 1907414
[TBL] [Abstract][Full Text] [Related]
9. Development and small-scale production of a severely heated factor VIII concentrate.
Knevelman A; de Wit HJ; Potstra P; vd Does JA
Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
[TBL] [Abstract][Full Text] [Related]
10. Virus validation experiments on the production process of OCTAVI SDPlus.
Biesert L; Lemon S; Suhartono H; Wang L; Rübsamen H
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S48-54. PubMed ID: 7495968
[TBL] [Abstract][Full Text] [Related]
11. Severely heated therapeutic factor VIII concentrate of high specific activity.
Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
13. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII:c concentrate virus inactivated: progress in purification by using classic chromatographic methods.
Arrighi S; Pacenti L; Borri MG
Vox Sang; 1993; 64(1):13-8. PubMed ID: 8447116
[TBL] [Abstract][Full Text] [Related]
15. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
Mannucci PM
Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
[TBL] [Abstract][Full Text] [Related]
17. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
[TBL] [Abstract][Full Text] [Related]
18. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
19. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
[TBL] [Abstract][Full Text] [Related]
20. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]